Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs.
about
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusThioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetesSan-Huang-Xie-Xin-Tang Constituents Exert Drug-Drug Interaction of Mutual Reinforcement at Both Pharmacodynamics and Pharmacokinetic Level: A ReviewCooperative anti-diabetic effects of deoxynojirimycin-polysaccharide by inhibiting glucose absorption and modulating glucose metabolism in streptozotocin-induced diabetic miceCurcumin prevents leptin raising glucose levels in hepatic stellate cells by blocking translocation of glucose transporter-4 and increasing glucokinaseProtein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus.Curcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2Skeletal muscle sodium glucose co-transporters in older adults with type 2 diabetes undergoing resistance training.Comprehensive evidence-based assessment and prioritization of potential antidiabetic medicinal plants: a case study from canadian eastern james bay cree traditional medicineImportant genetic checkpoints for insulin resistance in salt-sensitive (S) Dahl rats.Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.Modeling kinetics of subcellular disposition of chemicals.Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.Recent and emerging anti-diabetes targets.Impaired macrophage autophagy induces systemic insulin resistance in obesitySodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.Clinical implication of SGLT2 inhibitors in type 2 diabetes.Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo.The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect in insulin-resistant mice.Effects of Syzygium aromaticum-derived oleanolic acid on glucose transport and glycogen synthesis in the rat small intestine.Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity.Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
P2860
Q21195757-04312160-77ED-456E-8314-67A92B7F77D1Q24684670-CCCA5E20-C54B-4DDF-BD85-7EEDB4D11C03Q28075782-A8FCBCA0-0950-4B89-B0DB-A742791687C2Q28533699-E0E37B52-65EB-4CBB-809F-322E6F88840EQ28577564-EC81E025-AC8B-4494-8691-0161328F54B2Q34135843-6BA716BB-D838-4F0F-9631-2E17975A3CEAQ34574662-D59BA8F8-13ED-43A8-8EBB-5E71CC2E58B8Q34664910-1B28BDD0-F70D-4CE3-B3AB-B164C9AC6484Q35636775-7F0FB7D3-929E-462F-ADC7-EE81CECDB145Q36761492-8615B49A-0EC6-4CA9-8E71-F6379564D353Q36929947-BCDF9FB8-35D0-408B-8A1B-16262F1080B1Q37194304-16E60C93-04D3-48A3-9FE6-6F82BE7C9FC8Q37244353-F3C3A731-69BD-4E0D-8CFC-1A6AE0F8FFCBQ37294554-5612B173-9845-4D94-9CCB-0E3324B2E0F3Q37392527-33AAB60F-1672-4D8F-BB01-F86F064D1CEEQ37703184-E56F44B6-99CC-4DED-A195-BB3D59B9EECDQ37940036-6F9826EF-A7E3-4FCA-9843-60A40730CE1EQ38126109-6380CC83-D0A0-436A-A17E-5099056A1647Q38221980-9D408BD8-1FFB-486E-8FF8-2231BAAFA9B6Q38297265-F1FBB623-2A8C-4874-BE13-0B143FB1E0C7Q40106543-F98A953E-1CC0-4BED-B53D-A2A495C8BFDDQ43199877-3B3C5C4D-2AF5-4793-AD83-1DAFF2884DC5Q45095646-4BF39A1B-7F84-4BAF-BADD-21BE41B275F6Q47268877-07910BB9-9A23-47FF-9748-9F7D2CD5B0C4Q48785972-CF456978-BE54-4E99-86B9-7C103C8C617AQ55457178-EBDBBE11-312C-4835-81AC-FF4E25B85564
P2860
Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Glucose transporter and Na+/gl ...... argets of anti-diabetic drugs.
@ast
Glucose transporter and Na+/gl ...... argets of anti-diabetic drugs.
@en
type
label
Glucose transporter and Na+/gl ...... argets of anti-diabetic drugs.
@ast
Glucose transporter and Na+/gl ...... argets of anti-diabetic drugs.
@en
prefLabel
Glucose transporter and Na+/gl ...... argets of anti-diabetic drugs.
@ast
Glucose transporter and Na+/gl ...... argets of anti-diabetic drugs.
@en
P2093
P356
P1476
Glucose transporter and Na+/gl ...... argets of anti-diabetic drugs.
@en
P2093
Hideki Katagiri
Hideyuki Sakoda
Hiraku Ono
Hiroki Kurihara
Midori Fujishiro
Motonobu Anai
Takehide Ogihara
Tomoichiro Asano
Yasunobu Uchijima
P304
P356
10.2174/0929867043364360
P577
2004-10-01T00:00:00Z